Review Finds ADHD Pharmacotherapy Linked to Reduced Appetite and Transient Growth Effects

Key Takeaways

• A scoping review in Nutrients mapped 27 studies of nutrition-related outcomes in people with ADHD taking medication, and found that most evidence covers children and growth, with little on adults, biomarkers, or bone health.
• Stimulant treatment was associated with reduced appetite, lower energy intake during active treatment, and transient reductions in body weight, BMI, and growth velocity that often eased over time.
• Some studies reported a higher risk of disordered eating, and others reported improved dietary structure. The authors say most evidence is observational and can't establish causation.

Researchers at the University of Applied Sciences Muenster, led by Jens-Mirco Engbrink and Anja Markant, report a scoping review of how ADHD pharmacotherapy relates to dietary intake, eating behavior, nutritional status, growth, and bone health across the lifespan. They say appetite suppression is a well-known side effect, but its wider nutritional consequences had not been systematically mapped.

The team followed JBI methodology and PRISMA-ScR guidelines. They searched PubMed and Scopus for studies published from January 2010 to June 2026 and supplemented this with citation searching. Of 718 database records, 27 studies were included. Nearly all (25) were observational, and only two were randomized trials. Most involved mixed-age or pediatric populations, and adults appeared in just two studies. The team did not appraise study quality or preregister a protocol. Growth and anthropometric outcomes were the most studied (19 studies), followed by dietary intake and eating behavior (5), nutritional status and metabolic biomarkers (4), and bone health (2).

In children, stimulant treatment was associated with BMI z-score reductions of roughly 0.4 to 0.6 and slower height gain, mostly in the first 6 to 12 months. Longitudinal studies suggested these effects attenuated, with partial or complete catch-up, and amphetamine-based drugs caused more early weight loss than methylphenidate. Only one study measured energy intake directly. It found lower daily intake in medicated children, with a compensatory rise in the evening. Eating-behavior studies pointed both ways, with some reporting a higher risk of disordered eating and others improved dietary regularity. Biomarker findings, including ferritin and short-chain fatty acids, were limited and inconsistent. Bone data came from two studies, which reported lower bone mineral density in medicated children and about 6% lower density at some sites in adults.

The authors note that the study counts show how much research exists, not how strong the evidence is. Limitations include heterogeneous measures, age groups harmonized after the fact, and a search limited to two databases. They recommend monitoring weight, height, and BMI during treatment, watching appetite across the day, and basing supplementation on assessment rather than on stimulant use alone. They call for research that combines nutritional and psychiatric perspectives, with more focus on adults and long-term outcomes.